What smart money is saying about Ultragenyx Pharmaceutical
RARE
No fund has written a full thesis on Ultragenyx Pharmaceutical in our archive, but 1 fund letter reports a position in it, most recently Clearbridge Small Cap Strategy in September 2025.
Get an email when a fund buys, sells or pitches it
1
Reported positions
0
Bought
1
Sold
1
Letter
Position history
Every position in Ultragenyx Pharmaceutical on record in the archive was reported in Q3 2025, across 1 fund letter, with 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2025 | 1 | 0 | 1 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position · 1 move
- September 2025
“We exited positions in GoodRx and Ultragenyx Pharmaceutical in the health care sector, Oxford Industries in the consumer discretionary sector, Anterix in the communication services sector, Wabash National in the industrials sector, ASGN in the IT sector and LXP Industrial Trust in the real estate sector.”
Ultragenyx Pharmaceutical
Read the letters behind these Ultragenyx Pharmaceutical positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger